Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to daily self-administer AMG 337 orally as a whole capsule~* Male or female 18 years of age or over.~* Pathologically confirmed advanced G/GEJ/E adenocarcinoma (Cohort 1) or other solid tumor (Cohort 2) for which subject has received prior therapy for advanced disease, for which no standard therapy exists, or subject refuses standard therapy~* Tumor MET amplified by protocol-specified centralized testing.~* Measurable disease per RECIST 1.1 guidelines. Cohort 2 may include up to 10 subjects with advanced MET amplified, G/GEJ/E adenocarcinoma with non-measurable tumor per RECIST v1.1~* (ECOG) Performance Status of 0, 1 or 2~Exclusion Criteria:~* Known central nervous system metastases~* Candidate for curative surgery or definitive chemoradiation~* Peripheral edema \> grade 1~* Persistent gastric outlet obstruction, complete dysphagia or are dependent upon jejunostomy for feeding. Significant gastrointestinal disorder(s) that in the opinion of the Investigator may influence drug absorption~* Acute Hepatitis B. Chronic Hepatitis B eligible if condition is stable and, in the opinion of the investigator or Amgen physician, if consulted, would not pose a risk to subject safety~* Detectable Hepatitis C virus (indicative of active Hepatitis C)~* Currently receiving any anti-tumor treatments, or less than 14 days prior to enrollment since ending anti-tumor treatment~* Prior treatment with small molecule inhibitors of the MET pathway.~Other protocol defined inclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm (Type: EXPERIMENTAL): AMG 337 Monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).